LifeVantage (NASDAQ:LFVN) Coverage Initiated by Analysts at Craig Hallum

Craig Hallum began coverage on shares of LifeVantage (NASDAQ:LFVN) in a research note published on Tuesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $35.00 price target on the stock.

Separately, Lake Street Capital began coverage on shares of LifeVantage in a research note on Thursday, December 19th. They set a “buy” rating and a $26.00 price objective on the stock.

LifeVantage Trading Up 11.4 %

Shares of LFVN stock opened at $25.62 on Tuesday. LifeVantage has a twelve month low of $5.22 and a twelve month high of $27.38. The stock has a fifty day simple moving average of $16.07 and a two-hundred day simple moving average of $11.77. The stock has a market capitalization of $320.89 million, a price-to-earnings ratio of 80.07 and a beta of 0.82.

LifeVantage (NASDAQ:LFVN) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.15 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.15. The company had revenue of $47.21 million during the quarter. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%.

LifeVantage Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were given a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date was Monday, December 2nd. LifeVantage’s payout ratio is currently 50.00%.

Hedge Funds Weigh In On LifeVantage

A number of large investors have recently added to or reduced their stakes in LFVN. Ritholtz Wealth Management boosted its holdings in shares of LifeVantage by 62.0% in the 3rd quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock valued at $346,000 after buying an additional 10,974 shares in the last quarter. Barclays PLC boosted its stake in LifeVantage by 38.2% in the third quarter. Barclays PLC now owns 41,966 shares of the company’s stock valued at $507,000 after acquiring an additional 11,608 shares in the last quarter. HighTower Advisors LLC acquired a new stake in LifeVantage in the third quarter valued at approximately $638,000. Capital Management Corp VA purchased a new position in LifeVantage in the third quarter worth $5,073,000. Finally, Renaissance Technologies LLC increased its position in shares of LifeVantage by 2.1% during the second quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock worth $5,490,000 after purchasing an additional 17,300 shares in the last quarter. 35.32% of the stock is currently owned by institutional investors.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.